GeneDx Holdings financials
$72.32+0.03%
Close Oct 1, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $427.5M | $305.4M | $202.6M |
| Gross profit | $298.2M | $194.4M | $90.0M |
| Gross margin | 69.7% | 63.6% | 44.4% |
| Operating income | -$13.1M | -$23.2M | -$178.6M |
| Net income | -$21.0M | -$52.3M | -$175.8M |
| Net margin | −4.9% | −17.1% | −86.8% |
| Diluted EPS | $-0.73 | $-1.94 | $-7.23 |
| EBITDA | $12.1M | -$1.3M | -$134.5M |
| Operating cash flow | $33.3M | -$28.5M | -$180.1M |
| Free cash flow | $14.3M | -$34.0M | -$185.4M |
| Diluted shares | 28.6M | 26.9M | 24.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $105.0M | $85.2M | $99.7M |
| Short-term investments | $66.3M | $56.0M | $30.5M |
| Total debt | $48.2M | $51.9M | $52.7M |
| Total assets | $523.7M | $419.4M | $418.8M |
| Total liabilities | $215.5M | $174.1M | $190.7M |
| Shareholders' equity | $308.2M | $245.2M | $228.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology